AUTL241220P2500
- 0.20
- 0.000.00%
Autolus Therapeutics Newsroom
Autolus Therapeutics Analyst Ratings
Needham Maintains Autolus Therapeutics(AUTL.US) With Buy Rating, Maintains Target Price $10
Needham Maintains Autolus Therapeutics(AUTL.US) With Buy Rating, Maintains Target Price $10
Needham Reiterates Buy on Autolus Therapeutics, Maintains $10 Price Target
Goldman Sachs Upgrades Autolus Therapeutics(AUTL.US) to Buy Rating, Raises Target Price to $7.6
Autolus Therapeutics Analyst Ratings
Goldman Sachs Upgrades Autolus Therapeutics to Buy From Neutral, Adjusts Price Target to $7.60 From $7
Autolus Therapeutics Raised to Buy From Neutral by Redburn Atlantic
Redburn Atlantic Initiates Autolus Therapeutics(AUTL.US) With Buy Rating, Announces Target Price $13
Truist Financial Maintains Autolus Therapeutics(AUTL.US) With Buy Rating
Needham Reiterates Buy on Autolus Therapeutics, Maintains $10 Price Target
A Quick Look at Today's Ratings for Autolus Therapeutics(AUTL.US), With a Forecast Between $8 to $13
A Quick Look at Today's Ratings for Autolus Therapeutics(AUTL.US), With a Forecast Between $8 to $10
Analysts Offer Insights on Healthcare Companies: Autolus Therapeutics (AUTL), Molina Healthcare (MOH) and AnaptysBio (ANAB)
Truist Financial Maintains Autolus Therapeutics(AUTL.US) With Buy Rating
Needham Reiterates Buy on Autolus Therapeutics, Maintains $9 Price Target
Autolus Therapeutics Analyst Ratings
Needham Maintains Autolus Therapeutics(AUTL.US) With Buy Rating, Maintains Target Price $9
Truist Financial Maintains Autolus Therapeutics(AUTL.US) With Buy Rating
Truist Financial Maintains Autolus Therapeutics(AUTL.US) With Buy Rating